COMP <GO>
EUDA vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
EUDA Health Holdings Limited (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: EUDA 2
— MRK 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $15.50 (+1.31%) • MKT CAP: $46.4M
roic
-35.00%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EUDA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EUDA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 43.90% | 74.80% | -30.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.39% | 3.42% | -8.81 | MRK | /fcf-yield <GO> |
| Operating Margin | -36.30% | 34.30% | -70.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -40.70% | 28.10% | -68.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 70.00% | 1.30% | +68.70 | EUDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.7 | 51.7 | +7.99 | EUDA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $46.4M | $361.02B | -$360.97B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EUDA REV | MRK REV | EUDA GROSS % | MRK GROSS % | EUDA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.8M | $65.01B | 43.9% | 74.8% | -$2.5M | $12.36B |
| FY 2024 | $4.0M | $64.17B | 19.0% | 76.3% | -$2.1M | $18.10B |
| FY 2023 | $3.7M | $60.12B | — | — | -$2.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EUDA // BETA —
MRK // BETA 0.92